Table 1.
Clinical and laboratory characteristics of patients with psoriasis and the control group.
| Control Group (n = 40) |
Psoriasis (n = 80) |
Statistical Significance |
|
|---|---|---|---|
| Age (years) | 42.9 ± 12.7 | 42.5 ± 13.9 | 0.89 |
| Sex, men, n (%) | 28 (70%) | 54 (67.5%) | 0.84 |
| BMI (kg/m2) | 29.3 ± 6.1 | 29.8 ± 5.8 | 0.68 |
| Smoking, n (%) | 21 (52.5%) | 38 (47.5%) | 0.70 |
| Steatohepatitis, n (%) | 21 (52.5%) | 54 (67.5%) | 0.11 |
| Psoriasis duration (years) | - | 10.5 ± 6.4 | - |
| PASI score | - | 11.75 [7.45–16.8] | - |
| Neutrophil to lymphocyte ratio (NLR) | 1.72 [1.36–2.11] | 2.59 [1.96–3.09] | <0.01 |
| Glucose (mg/dL) | 87.9 ± 11.7 | 90.9 ± 10.5 | 0.78 |
| Total cholesterol (mg/dL) | 181.6 ± 18.6 | 188.7 ± 33.5 | 0.97 |
| LDL-cholesterol (mg/dL) | 106.8 ± 22.8 | 109.6 ± 36.2 | 0,76 |
| HDL-cholesterol (mg/dL) | 48.1 ± 15.8 | 46.6 ± 11.5 | 0.72 |
| Triglycerides (mg/dL) | 133.8 ± 45.7 | 143.8 ± 52.6 | 0.87 |
| AST (U/L) | 26.1 ± 13.4 | 27.4 ± 15.1 | 0.67 |
| ALT (U/L) | 32.8 ± 24.2 | 34.5 ± 24.8 | 0.75 |
| GGT (U/L) | 48.2 ± 57.3 | 55.9 ± 73.9 | 0.64 |
| Creatinine (mg/dL) | 0.84 ± 0.21 | 0.85 ± 0.19 | 0.90 |
| eGFR, (mL/min/1.73 m2) | 91.3 ± 25.7 | 89.8 ± 24.6 | 0.78 |
| CRP (mg/L) | 3.85 ± 4.8 | 4.03 ± 5.9 | 0.89 |
| I-FABP (pg/mL) | 114.38 [51.60–241.60] | 243.00 [108.88–787.10] | <0.001 |
Legend: BMI—body mass index, PASI—Psoriasis Area Severity Index, AST—aspartate aminotransferase, ALT—alanine aminotransferase, GGT—gamma-glutamyltransferase, eGFR— estimated glomerular filtration rate, CRP—C-reactive protein, I-FABP—intestinal fatty acid protein; Statistically significant values are in bold.